Literature DB >> 17262704

Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease.

Corinna La Rosa1, Ajit P Limaye, Aparna Krishnan, Jeff Longmate, Don J Diamond.   

Abstract

Cytomegalovirus (CMV)-seronegative recipients (R(-)) of a liver transplant from CMV-positive donors (D(+)) are at high risk for developing late CMV disease after discontinuation of antiviral prophylaxis. Levels of viremia and CMV-specific interferon (IFN)- gamma -producing CD4(+) and IFN- gamma -producing CD8(+) T cell responses were prospectively measured from discontinuation of antiviral prophylaxis until 1 year after transplantation in 17 consecutive D(+)/R(-) patients. CMV loads of >1000 copies/mL were strongly associated with CMV disease in the 6 symptomatic patients. Despite immunosuppression, broadly diverse T cells specific for CMV lysate or peptide libraries spanning pp65 and immediate early (IE) 1 immunodominant CMV antigens developed in all patients. A vigorous CD8(+) T cell response to pp65 and IE1 antigens characterized the D(+)/R(-) cohort. Unexpectedly, none of these responses were predictive of CMV disease or viremia. No significant lymphopenia or functional impairment of CMV-specific T cells was detected in the symptomatic patients, whose morbidity was resolved after antiviral treatment while measurable CMV immunity was maintained during the 1-year observation period.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17262704     DOI: 10.1086/511307

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

Authors:  Corinna La Rosa; Jeff Longmate; Simon F Lacey; Teodora Kaltcheva; Rahul Sharan; Denise Marsano; Peter Kwon; Jennifer Drake; Brenda Williams; Sharon Denison; Suenell Broyer; Larry Couture; Ryotaro Nakamura; Sanjeet Dadwal; Morris I Kelsey; Arthur M Krieg; Don J Diamond; John A Zaia
Journal:  J Infect Dis       Date:  2012-03-07       Impact factor: 5.226

2.  Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.

Authors:  Corinna La Rosa; Ajit P Limaye; Aparna Krishnan; Gideon Blumstein; Jeff Longmate; Don J Diamond
Journal:  Transpl Int       Date:  2011-06-14       Impact factor: 3.782

3.  Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients.

Authors:  Javier Carbone; Nallibe Lanio; Antonio Gallego; Florian Kern; Joaquin Navarro; Patricia Muñoz; Roberto Alonso; Pilar Catalán; Juan Fernández-Yáñez; Jesús Palomo; Manuel Ruiz; Eduardo Fernández-Cruz; Elizabeth Sarmiento
Journal:  J Clin Immunol       Date:  2012-02-29       Impact factor: 8.317

Review 4.  New developments in the management of cytomegalovirus infection after solid organ transplantation.

Authors:  Albert J Eid; Raymund R Razonable
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

5.  Association of the costimulatory molecule gene polymorphisms and active cytomegalovirus infection in hematopoietic stem cell transplant patients.

Authors:  Mahdiyar Iravani Saadi; Ramin Yaghobi; Mohammad Hossein Karimi; Bita Geramizadeh; Mani Ramzi; Maryam Zakerinia
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

6.  Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients.

Authors:  Manisha Patel; Martha Stefanidou; Caroline B Long; Melissa J Fazzari; Lydia Tesfa; Marcela Del Rio; Jacqueline Lamour; Rosanna Ricafort; Rebecca P Madan; Betsy C Herold
Journal:  Pediatr Transplant       Date:  2011-07-18

7.  Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection.

Authors:  Matthew R Pipeling; Erin E West; Christine M Osborne; Amanda B Whitlock; Lesia K Dropulic; Matthew H Willett; Michael Forman; Alexandra Valsamakis; Jonathan B Orens; David R Moller; Noah Lechtzin; Stephen A Migueles; Mark Connors; John F McDyer
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models.

Authors:  Aparna Krishnan; Zhongde Wang; Tumul Srivastava; Ravindra Rawal; Pooja Manchanda; Don J Diamond; Corinna La Rosa
Journal:  Immunol Lett       Date:  2008-08-13       Impact factor: 3.685

9.  Increased programmed death-1 molecule expression in cytomegalovirus disease and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Authors:  Ghislaine M Gallez-Hawkins; Lia Thao; Joycelynne Palmer; Andrew Dagis; Xiuli Li; Anne E Franck; Bernard Tegtmeier; Simon F Lacey; Don J Diamond; Stephen J Forman; John A Zaia
Journal:  Biol Blood Marrow Transplant       Date:  2009-07       Impact factor: 5.742

10.  In vitro cell-mediated immune responses of human immunodeficiency virus-infected and -uninfected individuals to whole cytomegalovirus antigens and their subunits.

Authors:  A Weinberg; J Spritzler; M Nokta; R Schrier; A Landay; D Brown; R Pollard
Journal:  Clin Vaccine Immunol       Date:  2008-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.